COMBINATION CHEMOTHERAPY WITH VINCRISTINE AND METHOTREXATE FOR ADVANCED REFRACTORY BREAST-CANCER

被引：0

作者：

YAP, HY

BLUMENSCHEIN, GR

TASHIMA, CK

HORTOBAGYI, GN

BUZDAR, AU

WISEMAN, CL

机构：

[1] Department of Medicine, Medical Breast Service, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas

来源：

CANCER | 1979年 / 44卷 / 01期

关键词：

D O I：

10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal. Copyright © 1979 American Cancer Society

引用

页码：32 / 34

页数：3

共 19 条

[1]

ANDREWS NEIL C., 1967, CANCER CHEMOTHER REP, V51, P471

[2]

BLUM RH, 1975, CANCER CHEMOTHER REP, V6, P399

[3]

BLUMENSC.GR, 1974, P AM ASSOC CANC RES, V15, P193

[4]

BULL JM, 1978, CANCER, V41, P1649, DOI 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO

[5]

2-J

[6]

GREENING WP, 1962, METHOTREXATE TREATME, P29

[7]

GRINBERG R, 1965, Cancer Chemother Rep, V45, P57

[8] CHEMOIMMUNOTHERAPY OF ADVANCED BREAST-CANCER - PROLONGATION OF REMISSION AND SURVIVAL WITH BCG [J].

GUTTERMAN, JU ;

CARDENAS, JO ;

BLUMENSCHEIN, GR ;

HORTOBAGYI, G ;

BURGESS, MA ;

LIVINGSTON, RB ;

MAVLIGIT, GM ;

FREIREICH, EJ ;

GOTTLIEB, JA ;

HERSH, EM .

BRITISH MEDICAL JOURNAL, 1976, 2 (6046) :1222-1225

[9]

HORTOBAGYI GN, 1979, CANCER, V43, P1225, DOI 10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO

[10]

2-6

← 1 2 →